Anidulafungin
- Generic Name
- Anidulafungin
- Brand Names
- Ecalta, Eraxis
- Drug Type
- Small Molecule
- Chemical Formula
- C58H73N7O17
- CAS Number
- 166663-25-8
- Unique Ingredient Identifier
- 9HLM53094I
- Background
Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.
- Indication
用于治疗食管念珠菌感染，念珠菌性败血症，念珠菌引起的腹腔脓肿及念珠菌性腹膜炎。
- Associated Conditions
- Bloodstream Infections (BSI), Candidemia, Candidiasis, Esophageal Candidiasis, Fungal peritonitis caused by Candida, Intraabdominal Abscess caused by Candida, Invasive Aspergillosis, Oropharyngeal Candidiasis
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2010-02-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00940017
- Locations
- 🇺🇸
Pfizer Investigational Site, Hartford, Connecticut, United States
Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment
- Conditions
- Ventilator Associated PneumoniaRespiratory Tract Infection
- Interventions
- Other: Normal Saline
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Daren K. Heyland
- Target Recruit Count
- 61
- Registration Number
- NCT00934934
- Locations
- 🇨🇦
Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
🇨🇦Hopital du Sacre-Coeur do Montreal, Montreal, Quebec, Canada
🇨🇦Hamilton Health Sciences Centre, Hamilton, Ontario, Canada
Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2009-05-04
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 10
- Registration Number
- NCT00892359
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients
- Conditions
- Central Nervous System Fungal InfectionsMycosesFungemiaLung Diseases, Fungal
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 200
- Registration Number
- NCT00841971
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸UCLA Medical Cente, Los Angeles, California, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
- Conditions
- FungemiaNeutropeniaCandidiasis
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2012-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00806351
- Locations
- 🇸🇰
Pfizer Investigational Site, Kosice, Slovakia
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida
- Conditions
- CandidiasisFungemia
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT00805740
- Locations
- 🇨🇭
Pfizer Investigational Site, Geneve 14, Switzerland
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT00761267
- Locations
- 🇧🇷
Hospital Pequeno Principe, Curitiba, PR, Brazil
🇰🇷Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of
🇺🇸University of California - Los Angeles - Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
Anidulafungin PK in Infants and Toddlers
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2012-11-21
- Lead Sponsor
- Michael Cohen-Wolkowiez
- Target Recruit Count
- 15
- Registration Number
- NCT00734500
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
- Conditions
- Invasive Candidiasis
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 216
- Registration Number
- NCT00689338
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients
- Conditions
- Invasive Candidiasis
- Interventions
- Drug: Empiric antifungal therapy based on physician discretion.
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Duke University
- Target Recruit Count
- 64
- Registration Number
- NCT00672841
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.